Login Register Cart 0
Generic placeholder image

Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1573-4064
ISSN (Online): 1875-6638

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

A Comprehension into Target Binding and Spatial Fingerprints of Noscapinoid Analogues as Inhibitors of Tubulin

Author(s): Seema Mandavi, Sant Kumar Verma, Laxmi Banjare, Amit Dubey, Renu Bhatt*, Suresh Thareja* and Akhlesh Kumar Jain*

Volume 17, Issue 6, 2021

Published on: 17 January, 2020

Page: [611 - 622] Pages: 12

DOI: 10.2174/1573406416666200117120348

Price: $65

Abstract

Background: Owing to its potential to interfere in microtubule dynamics in the mitotic phase of cell cycle and selectively induce apoptosis in cancer cells without affecting normal cells, noscapine and its synthetic analogues have been investigated by other research groups in different cell lines for their capability to be used as anti-cancer agents.

Objective: The present study is focused on the investigation of the mode of binding of noscapinoids with tubulin, prediction of target binding affinities and mapping of their spatial fingerprints (shape and electrostatic).

Methods: Molecular docking assisted alignment based 3D-QSAR was used on a dataset (43 molecules) having an inhibitory activity (IC50 = 1.2-250 μM) against human lymphoblast (CEM) cell line.

Results and Conclusion: Key amino acid residues of target tubulin were mapped for the binding of most potent noscapine analogue (Compound 11) and were compared with noscapine. Spatial fingerprints of noscapinoids for favorable tubulin inhibitory activity were generated and are proposed herewith for further pharmacophoric amendments of noscapine analogues to design and develop novel potent noscapine based anti-cancer agents that may enter into drug development pipeline.

Keywords: Anticancer agents, 3D-QSAR, noscapine analogues, molecular docking, spatial fingerprints, tubulin inhibitors.

« Previous Next »
Graphical Abstract

[1]
Zugazagoitia J, Guedes C, Ponce S, Ferrer I, Molina Pinelo S, Paz-Ares L. Current challenges in cancer treatment. Clin Ther 2016; 38(7): 1551-66.
[http://dx.doi.org/10.1016/j.clinthera.2016.03.026] [PMID: 27158009]
[2]
World Health Organization. Cancer key facts https://www.who.int/en/news-room/fact-sheets/detail/cancer2019
[3]
Hassanpour SH, Dehghani M. Review of cancer from perspective of molecular. J Cancer Res Pract 2017; 4: 127-9.
[http://dx.doi.org/10.1016/j.jcrpr.2017.07.001]
[4]
Fernando J, Jones R. The principles of cancer treatment by chemotherapy. Surgery 2015; 33: 131-5.
[5]
Sudhakar A. History of Cancer, ancient and modern treatment methods. J Cancer Sci Ther 2009; 1(2): 1-4.
[http://dx.doi.org/10.4172/1948-5956.100000e2] [PMID: 20740081]
[6]
Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004; 4(4): 253-65.
[http://dx.doi.org/10.1038/nrc1317] [PMID: 15057285]
[7]
Mishra RC, Karna P, Gundala SR, et al. Second generation benzofuranone ring substituted noscapine analogs: synthesis and biological evaluation. Biochem Pharmacol 2011; 82(2): 110-21.
[http://dx.doi.org/10.1016/j.bcp.2011.03.029] [PMID: 21501599]
[8]
Naik PK, Chatterji BP, Vangapandu SN, et al. Rational design, synthesis and biological evaluations of amino-noscapine: a high affinity tubulin binding noscapinoid. J Comput Aided Mol Des 2011; 25(5): 443-54.
[http://dx.doi.org/10.1007/s10822-011-9430-4] [PMID: 21544622]
[9]
Manchukonda NK, Naik PK, Sridhar B, Kantevari S. Synthesis and biological evaluation of novel biaryl type alpha noscapine congeners. Bioorg Med Chem Lett 2014; 24(24): 5752-7.
[http://dx.doi.org/10.1016/j.bmcl.2014.10.046] [PMID: 25453814]
[10]
Mishra RC, Gundala SR, Karna P, et al. Design, synthesis and biological evaluation of di-substituted noscapine analogs as potent and microtubule-targeted anticancer agents. Bioorg Med Chem Lett 2015; 25(10): 2133-40.
[http://dx.doi.org/10.1016/j.bmcl.2015.03.076] [PMID: 25891106]
[11]
Afzali M, Ghaeli P, Khanavi M, et al. Non-addictive opium alkaloids selectively induce apoptosis in cancer cells compared to normal cells. Daru 2015; 23: 16-23.
[http://dx.doi.org/10.1186/s40199-015-0101-1] [PMID: 25890335]
[12]
Porcu E, Sipos A, Basso G, et al. Novel 9-substituted-noscapines: synthesis with Suzuki cross-coupling, structure elucidation and biological evaluation. Eur J Med Chem 2014; 84: 476-90.
[http://dx.doi.org/10.1016/j.ejmech.2014.07.050] [PMID: 25050880]
[13]
Manchukonda NK, Naik PK, Santoshi S, et al. Rational design, synthesis, and biological evaluation of third generation alpha-noscapine analogues as potent tubulin binding anti-cancer agents. PLoS One 2013; 8(10)e77970
[http://dx.doi.org/10.1371/journal.pone.0077970] [PMID: 24205049]
[14]
Verma AK, Bansal S, Singh J, et al. Synthesis and in vitro cytotoxicity of haloderivatives of noscapine. Bioorg Med Chem 2006; 14(19): 6733-6.
[http://dx.doi.org/10.1016/j.bmc.2006.05.069] [PMID: 16784870]
[15]
Naik PK, Chatterji BP, Vangapandu SN, et al. Rational design, synthesis and biological evaluations of amino-noscapine: a high affinity tubulin-binding noscapinoid. J Comput Aided Mol Des 2011; 25(5): 443-54.
[http://dx.doi.org/10.1007/s10822-011-9430-4] [PMID: 21544622]
[16]
Aneja R, Vangapandu SN, Joshi HC. Synthesis and biological evaluation of a cyclic ether fluorinated noscapine analog. Bioorg Med Chem 2006; 14(24): 8352-8.
[http://dx.doi.org/10.1016/j.bmc.2006.09.012] [PMID: 17008104]
[17]
Verma SK, Sharma SK, Suresh S. docking study of novel pyrrolidine derivatives as potential dipeptidyl peptidase-IV (DPP-IV) inhibitors. Lett Drug Des Discov 2015; 12: 284-91.
[http://dx.doi.org/10.2174/1570180811666141016000752]
[18]
Verma SK, Rajpoot T, Gautam MK, Jain AK, Thareja S. Design of novel biphenyl-2-thioxothiazolidin-4-one derivatives as potential protein tyrosine phosphatase (PTP)-1B inhibitors using molecular docking study. Lett Drug Des Discov 2016; 13: 295-300.
[http://dx.doi.org/10.2174/1570180812666150819002954]
[19]
Banjare L, Verma SK, Jain AK, Thareja S. Lead molecules as novel aromatase inhibitors: in silico de novo designing and binding affinity studies. Lett Drug Des Discov 2020; 17: 655-65.
[http://dx.doi.org/10.2174/1570180816666190703152659]
[20]
Thareja S, Verma SK, Haksar D, Bhardwaj TR, Kumar M. Discovery of novel cinnamylidene-thiazolidinedione derivatives as PTP-1B inhibitors for the management of type 2 diabetes. RSC Advances 2016; 6: 108928-40.
[http://dx.doi.org/10.1039/C6RA24501C]
[21]
Verma SK, Jain AK. Molecular docking simulations as a prominent tool to envisage the preformulation perspectives of oral hypoglycaemic agents with beta-cyclodextrin. Lett Drug Des Discov 2017; 14: 1283-90.
[http://dx.doi.org/10.2174/1570180814666170420125907]
[22]
Verma SK, Thareja S. Structure based comprehensive modelling, spatial fingerprints mapping and ADME screening of curcumin analogues as novel ALR2 inhibitors. PLoS One 2017; 12(4)e0175318
[http://dx.doi.org/10.1371/journal.pone.0175318] [PMID: 28399135]
[23]
Thareja S. Steroidal 5α-reductase inhibitors: a comparative 3D-QSAR study review. Chem Rev 2015; 115(8): 2883-94.
[http://dx.doi.org/10.1021/cr5005953] [PMID: 25785489]
[24]
Verma S, Thareja S. Formylchromone derivatives as novel and selective PTP-1B inhibitors: a drug design aspect using molecular docking-based self-organizing molecular field analysis. Med Chem Res 2016; 25: 1433-67.
[http://dx.doi.org/10.1007/s00044-016-1584-0]
[25]
Banjare L, Verma SK, Jain AK, Thareja S. Structure guided molecular docking assisted alignment dependent 3D-QSAR study on steroidal aromatase inhibitors (SAIs) as anti-breast cancer agents. Lett Drug Des Discov 2019; 16: 808-17.
[http://dx.doi.org/10.2174/1570180815666181010101024]
[26]
Verma SK, Thareja S. Molecular docking assisted 3D-QSAR study of benzylidene-2,4-thiazolidinedione derivatives as PTP-1B inhibitors for the management of type-2 diabetes mellitus. RSC Advances 2016; 6: 33857-67.
[http://dx.doi.org/10.1039/C6RA03067J]

Rights & Permissions Print Cite
Article Metrics
25
1
© 2024 Bentham Science Publishers | Privacy Policy